Jupiter Neurosciences, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical firm focused on the discovery and advancement of therapies for neuro-inflammation. The company leverages its proprietary JOTROL™ resveratrol platform, designed to deliver enhanced bioavailability and therapeutic levels without the typical gastrointestinal issues. Its robust pipeline includes several candidates undergoing development: JNS101 is progressing through Phase II trials for Friedreich's Ataxia, a rare inherited neurological disorder, and JNS102 is also in Phase II for Mucopolysaccharidosis Type I. Additionally, JNS107 is in Phase II for MELAS Syndrome, and JNS108 is in Phase II development for mild cognitive impairment and early Alzheimer's disease. Most recently, JOTROL™ received FDA IND clearance for its Phase 2a clinical trial in Parkinson's disease, with patient enrollment anticipated in early 2026. The company is also conducting early-stage development for JNS109 targeting amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 for COVID-19 treatment. Established in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., rebranded to Jupiter Neurosciences, Inc. in August 2021. Its headquarters are located in Jupiter, Florida. Beyond its pharmaceutical pipeline, the company is strategically expanding into the consumer longevity market with its Nugevia™ product line, set to launch in Q3 2025.
Company News
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Increase in Short Interest